We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.54%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$5.12B
AUM Growth
-$493M
(-8.8%)
Cap. Flow
-$685M
Cap. Flow
% of AUM
-13.38%
Top 10 Holdings %
Top 10 Hldgs %
51.39%
Holding
136
New
20
Increased
23
Reduced
33
Closed
42
Avg Time Held Equity + Options
6.2
quarters
Top 10 Avg Time Held Equity + Options
2.8
quarters
Top 20 Avg Time Held Equity + Options
2.8
quarters
Avg Time Held Equity only
6.3
quarters
Top 10 Avg Time Held Equity only
2.9
quarters
Top 20 Avg Time Held Equity only
2.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$101M |
| 2 |
Relay Therapeutics
RLAY
|
+$70.2M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$59.9M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$39.8M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$33.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exact Sciences
EXAS
|
+$122M |
| 2 |
Arcellx
ACLX
|
+$95.6M |
| 3 |
Boston Scientific
BSX
|
+$93.3M |
| 4 |
Amicus Therapeutics
FOLD
|
+$90.7M |
| 5 |
Astria Therapeutics
ATXS
|
+$84.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.61% |
| 2 | Miscellaneous | 1.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Nautilus Biotechnolgy
NAUT
$261M
| $48.9M | 0.95% |
12,594,211
| – | – |
2021 Q2
19 quarters
|
|
27
CytomX Therapeutics
CTMX
$508M
| $47.5M | 0.93% |
10,098,824
+418,639
| +4% | +$2.12M |
2025 Q2
3 quarters
|
|
28
Alto Neuroscience
ANRO
$867M
| $45.2M | 0.88% |
2,009,893
+225,500
| +13% | +$4.18M |
2025 Q3
2 quarters
|
|
29
enGene Therapeutics
ENGN
$109M
| $39.7M | 0.78% |
5,827,506
-41,570
| -0.7% | -$370K |
2025 Q3
2 quarters
|
|
30
Immunovant
IMVT
$5.93B
| $39.7M | 0.78% |
1,597,383
-397,507
| -20% | -$10.3M |
2022 Q4
13 quarters
|
|
31
Intuitive Surgical
ISRG
$149B
| $39.4M | 0.77% |
85,419
-2,500
| -3% | -$1.26M |
2023 Q4
9 quarters
|
|
|
32
Ionis Pharmaceuticals
IONS
$7.04B
| $37.8M | 0.74% |
+504,000
| New | +$39.8M |
2026 Q1
0 quarters
|
|
33
DELISTED
Day One Biopharmaceuticals
DAWN
| $37.6M | 0.74% |
+1,755,799
| New | +$24.7M |
2026 Q1
0 quarters
|
|
34
Abivax
ABVX
$7.52B
| $36.6M | 0.72% |
328,884
-129,459
| -28% | -$15.3M |
2025 Q3
2 quarters
|
|
35
Corvus Pharmaceuticals
CRVS
$792M
| $33.5M | 0.66% |
2,292,441
+1,600,000
| +231% | +$25.5M |
2025 Q2
3 quarters
|
|
36
Repligen
RGEN
$11.1B
| $33.1M | 0.65% |
280,541
-35,000
| -11% | -$4.89M |
2025 Q1
4 quarters
|
|
37
Jazz Pharmaceuticals
JAZZ
$13.7B
| $32.1M | 0.63% |
170,000
| – | – |
2025 Q4
1 quarter
|
|
|
DMRA
38
Damora Therapeutics
DMRA
$1.15B
| $31.7M | 0.62% |
+1,223,000
| New | +$31.4M |
2026 Q1
0 quarters
|
|
39
X4 Pharmaceuticals
XFOR
$258M
| $27.8M | 0.54% |
6,737,648
+423,196
| +7% | +$1.59M |
2025 Q4
1 quarter
|
|
40
Guardant Health
GH
$21.8B
| $27.7M | 0.54% |
300,000
+140,000
| +88% | +$14.1M |
2025 Q4
1 quarter
|
|
41
Bright Minds Biosciences
DRUG
$507M
| $27.5M | 0.54% |
377,544
-71,746
| -16% | -$5.78M |
2024 Q4
5 quarters
|
|
42
Invivyd
IVVD
$190M
| $27.1M | 0.53% |
20,859,303
-925,863
| -4% | -$1.7M |
2025 Q4
1 quarter
|
|
43
Sionna Therapeutics
SION
$198M
| $26.4M | 0.52% |
658,439
-520,659
| -44% | -$19.9M |
2025 Q1
4 quarters
|
|
44
Axsome Therapeutics
AXSM
$8.19B
| $25.3M | 0.5% |
149,950
+1,050
| +0.7% | +$181K |
2023 Q2
11 quarters
|
|
45
Revolution Medicines
RVMD
$40.4B
| $25.1M | 0.49% |
+258,600
| New | +$26.1M |
2026 Q1
0 quarters
|
|
46
SAB Biotherapeutics
SABS
$244M
| $24.6M | 0.48% |
6,431,743
+5,628,533
| +701% | +$22.4M |
2025 Q4
1 quarter
|
|
47
Belite Bio
BLTE
$6.12B
| $24.2M | 0.47% |
151,979
-262,260
| -63% | -$44.1M |
2025 Q3
2 quarters
|
|
48
Tenax Therapeutics
TENX
$59.9M
| $23.2M | 0.45% |
1,447,782
+1,008,640
| +230% | +$13.6M |
2025 Q4
1 quarter
|
|
49
Axogen
AXGN
$2.12B
| $23.1M | 0.45% |
697,312
-86,828
| -11% | -$2.82M |
2025 Q4
1 quarter
|
|
50
Viridian Therapeutics
VRDN
$2.06B
| $22.9M | 0.45% |
1,170,829
-1,871,874
| -62% | -$55.6M |
2021 Q2
19 quarters
|
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Perceptive Advisors held 136 positions worth $5.12B, down 8.8% from $5.61B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Perceptive Advisors withdrew a net $685M in Q1 2026, closing 42 positions and reducing 33 holdings. Its most notable exit was Exact Sciences, an estimated $122M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Miscellaneous.
Against the trend, Perceptive Advisors opened a new position in Ionis Pharmaceuticals worth $37.8M.
- Perceptive Advisors's largest Q1 2026 buy was Ionis Pharmaceuticals: 504,000 shares worth $37.8M.
- Perceptive Advisors added most to Ascendis Pharma A/S in Q1 2026, an estimated $101M increase.
- Perceptive Advisors's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $57.4M.
- Perceptive Advisors fully exited Exact Sciences in Q1 2026, selling an estimated $122M.
- Perceptive Advisors's ten largest holdings make up 51% of its $5.12B portfolio in Q1 2026.
- Perceptive Advisors opened 20 new positions and closed 42 in Q1 2026.
- Perceptive Advisors's portfolio value fell 8.8% quarter-over-quarter to $5.12B.
Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.